Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan A Burger

Showing results (161-170 of 223) with videos related to

Pageof 23
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2016
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune CharacteristicsCandida Vitale, Lorenzo Falchi, Elisa Ten Hacken, et al.
The Journal of Clinical Investigation|November 23, 2021
B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemiaAndrea N Mazzarello, Eva Gentner-Göbel, Marcus Dühren-von Minden, et al.
Blood|July 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLLJan A Burger, Paul M Barr, Tadeusz Robak, et al.
American Journal of Hematology|January 23, 2016
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Elias J Jabbour, et al.
Blood|January 3, 2020
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factorsPaolo Strati, Ellen J Schlette, Luisa M Solis Soto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Leukemia Research|September 10, 2020
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemiaIsabelle G Solman, Lisa K Blum, Hana Y Hoh, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
Haematologica|November 8, 2011
Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevancePreetesh Jain, Mohammad Javdan, Franziska K Feger, et al.
American Journal of Hematology|December 29, 2018
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I studyPaul A Hamlin, Ian W Flinn, Nina Wagner-Johnston, et al.
Pageof 23

Showing results (161-170 of 223) with videos related to

Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2016
Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune CharacteristicsCandida Vitale, Lorenzo Falchi, Elisa Ten Hacken, et al.
The Journal of Clinical Investigation|November 23, 2021
B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemiaAndrea N Mazzarello, Eva Gentner-Göbel, Marcus Dühren-von Minden, et al.
Blood|July 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLLJan A Burger, Paul M Barr, Tadeusz Robak, et al.
American Journal of Hematology|January 23, 2016
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemiaNicholas J Short, Hagop M Kantarjian, Elias J Jabbour, et al.
Blood|January 3, 2020
Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factorsPaolo Strati, Ellen J Schlette, Luisa M Solis Soto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2011
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemiaWilliam G Wierda, Susan O'Brien, Xuemei Wang, et al.
Leukemia Research|September 10, 2020
Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemiaIsabelle G Solman, Lisa K Blum, Hana Y Hoh, et al.
Leukemia|May 18, 2018
Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesPhilip A Thompson, Christine B Peterson, Paolo Strati, et al.
Haematologica|November 8, 2011
Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevancePreetesh Jain, Mohammad Javdan, Franziska K Feger, et al.
American Journal of Hematology|December 29, 2018
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I studyPaul A Hamlin, Ian W Flinn, Nina Wagner-Johnston, et al.
Pageof 23